2. Because we understand diversity
International expansion
EU Markets
East Europe
CIS
Brazil
Mexico
Colombia
Central America
Chile
Peru
Ecuador
Argentina
Thailand
Malaysia
Philippines
Cambodia
Myanmar
Vietnam
More than 100 projects
developed worlwide
MENA
Markets
Taiwan
Hong Kong
Australia
3. Our strengths
• + 10 years helping companies to access new markets.
• More than 100 projects performed globally
• Most powerful databases
• IMS international (70 markets)
• Emerpgharma Panel / Linkedin (+50.000 1st line
connections, 4.000 companies, 102 countries)
• Tailor made services at a fraction of the usual cost
• Business intelligence for middle size companies
• One stop-shop service from concept design / gap
analysis to project execution and follow-up
We save time & money to our clients
4. Our team
• Mix of talented experienced professionals
and young executives.
• Experts & Hands-on professionals trained in
Top and Middle Size Pharmaceutical
Companies
5. Our services
• Markets targeting & prioritization
• Portfolio evaluation
• Pricing Strategy
• Entry strategy design
• In / out licensing / distribution partnering
• Business intelligence
• Regulatory strategy
• Generic business
• Local services subcontracting (analysis, release,
serialization)
• Access to market (tender bidding)
6. Markets Priority Assessment
Filtering Markets
• Low potential
• High entry barriers
• Improbable ROI
Accessible Markets Scope
• 3-5 years scenario
• Necessary budget according to
available resources
• Ensure reliability of data
Market Potential of Accessible
markets
• Size
• Growth
• Accessible Segments for our
products
• Regional approach
• Risk Management
We provide a
tested
methodology to
support our
clients in
decision making
7. Market Trends
Innovation
Finance /
Pricing
ManufacturingDesign
Markeeting /
Commercial
Category /
Competition
7
Does the product fit on the market trend?
What is the existing perception about the product?
Does the product fit on the three core qualities
customers expect from this product category?
Kind and level of innovation:
new entity, different
formulation, new design,
manufacturing process?
What spontaneous demand can
be expected? Is the innovation
relevant for the customer?
What is the market price for
similar products?
Is the market willing to
accept a premium price?
P&l healthy at the acceptable
selling prices, considering all
intermediaries?
Capacity enough for the
forecasted demand?
Contingency plans?
Is the existing design appropriate
for other markets?
What local adaptations should be
necessary?
Are local branding
investments required? Costs?
What kind of local
commercial activities must
be done to be successful with
the product?
How is the category champion
performing?
How performed last competitor
entering the market?
Are many new launches expected?
Portfolio evaluation is critical to fix realistic expectations
8. Price assessment
Tools to identify if the expected price is
enough to cover internal expenses and
provide benefits
9. Entry Strategy
• Evaluate company capabilities
• Identify options fitting customer’s strategy
• Design competitive Business Plans
• Evaluate business potential and risk assessment
• Support in decision making process
• Support in due diligence
• Local follow-up by experienced teams
Outlicensing
agreement
Distribution
partner
Hosting
Acquisition /
Joint
Venture
Subsidiary
Opening
10. In / Out licensing: Project Management
Project definition
Teaser
preparation
Partners
searching
Term Sheet
Agreement
Contract
Agreement
Asses Company
Needs
Asses ideal
partner
Unique Selling
Point / requested
product
Templates
Delivery
Draft
evaluation
Final Design
Market
Search
First Contacts
NDA
exchange /
Info Exchange
Negotiation
Grid
Preparation
Negotiations
procces
Term sheet
exchange
Final
negotiations
Contract
Review
Customer
assistance in
signature
Tailor
made
strategy
11.
12. Regulatory strategy
• Pharmaceutical
products
• Medical devices
• Food supplements
• FSMP (Food for special
medical purposes)
• Phytotherapeutics
• Traditional medicine
• EU markets
• Centralized procedure
• DCP procedure
• Local registration
• ASEAN markets
• LATAM markets
• MENA markets
A well designed regulatory strategy will save up to 30% costs and avoid
unnecessary delays
13. Generics Market
• Access to hospital tenders in:
• Spain
• Germany
• France
• Italy
• UK
• Nordic Countries
• Subcontract of local conditioning
• Release & Analysis
• Serialization
• Business intelligence in Generics & Biosimilars
• Generics Market Germany 2016-2018
• Biosimilars EU market 2018
14. Fees
• Retainer
• Depending on the project. Emergpharma will
establish a minimum retailer of 500 € / month
• Success fee
• Will be fixed based on contract, sales and in
special occasions in intermediary milestones
(term sheet signature, etc..)
• Anticipated contract finalization
• The client will be allowed to cancel the
agreement without any compensation if
milestones are not met in 2 months
15. Business cases
1. Market prioritization
• Pediatric food EU country leader to enter
ASEAN
2. Portfolio evaluation
• Asian company to enter Eu market with a broad
spectrum of hospital injectables (Antibiotics, Onco )
3. Pricing strategy
• European manufacturer assessing hospital tenders in
Italy and Spain required an updated review of prices
region by region.
4. Entry strategy
• South European company required an evaluation of a
subsidiary opening in Germany
• German specialized CRO looking for expansion in
south Europe asked for different options
• German manufacturer of insulin devices looking for
right entry strategy for APAC markets
16. Business cases (II)
5. In/out licensing
• South EU manufacturer looking for distributors in Vietnam,
Thailand, Myanmar, Philippines and Taiwan
• Indian company looking for products in CNS for core 5 EU
markets
• South EU company specialized in medical devices looking for
partners for outlicensing
• Chinese company looking for partners for hospital generics in
EU markets
• EU based company looking for partners in LATAM: Colombia
& Central America
6. Distribution partner searching
• South EU manufacturer looking for distributors in Vietnam,
Thailand, Myanmar, Philippines and Taiwan
17. Business cases (III)
7. Business intelligence
• Evaluation of the Generics market in Germany 2016-2018
• Biosimilars in Europe: last 3 years evolution & perspectives
8. Regulatory strategy
• Evaluation of a border line product strategy in CNS to speed
up access to market through EFSA
• Medical devices pathway for an antiobesity
• Regulatory pathways for traditional medicine based product
• Regulatory pathway for hospital injectable generics
(antiinfectives)
• Support required to get approval in Brazil (ANVISA), Mexico
and Chile for EU DCP approved hospital products
18. Business cases (IV)
9. Generics
• Subcontracting searching to reduce analysis & Release cost
by 60% for a Chinese generics company
• Pricing evaluation for tenders strategy in Spain, France,
Germany and Italy for a non European manufacturer of
generics in Oncology, CNS, urology & Antivirals
More detailed information about business cases on
demand (respecting confidentiality agreements)
19. Contact us
• EUROPE
• C/ Senora Sergia, 2
• 28250 Torrelodones (Madrid)
• SPAIN
• Mob. +34 67669993
• ASIA
• 105/48 Moo 4 Tamboon
• 21130 Ban Chang (Rayong)
• THAILAND
• Mob. +66 629659199
• Ignacio.diaz@emergpharmalinks.com